WallStSmart
ALT

Altimmune Inc

NASDAQ: ALT · HEALTHCARE · BIOTECHNOLOGY

$2.60
-1.14% today

Updated 2026-04-30

Market cap
$511.15M
P/E ratio
P/S ratio
12,467.17x
EPS (TTM)
$-1.00
Dividend yield
52W range
$3 – $8
Volume
4.1M

Altimmune Inc (ALT) Earnings

Quarterly earnings history, analyst estimates, and stock price reaction.

EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+12.7%
Last 4 quarters
Revenue YoY growth
+420.0%
Most recent quarter
EPS YoY growth
+18.2%
Most recent quarter

Earnings surprise history (last 12 quarters)

Beat estimate Missed estimate

Quarterly EPS and revenue trend

Quarterly revenue EPS (diluted)

How the stock reacts to earnings

Avg 1-day reaction
+0.4%
Last 2 reports
Positive reaction rate
50%
1 of 2 quarters
Largest single-day move
+9.6%
2025-11-06
Report dateEPS actualSurpriseClose beforeClose after1-day reaction
2026-03-26$-0.27-8.4%$3.31$3.02-8.8%
2025-11-06$-0.21+22.2%$3.75$4.11+9.6%

Quarterly earnings history

Fiscal quarter endingEPS estimateEPS actualSurpriseRevenueYoY revenue
2025-12-31$-0.25$-0.27-8.4%$26000.00+420.0%
2025-09-30$-0.27$-0.21+22.2%$5000.00+0.0%
2025-06-30$-0.31$-0.27+12.9%$5000.00+0.0%
2025-03-31$-0.34$-0.26+23.9%$5000.00+0.0%
2024-12-31$-0.34$-0.33+1.5%$5000.00-86.5%
2024-09-30$-0.35$-0.32+8.2%$5000.00-98.6%
2024-06-30$-0.34$-0.35-2.9%$5000.00-16.7%
2024-03-31$-0.37$-0.34+8.1%$5000.00-76.2%
2023-12-31$-0.43$-0.33+23.3%$37000.00
2023-09-30$-0.42$-0.39+7.1%$362000.00
2023-06-30$-0.46$-0.32+30.4%$6000.00
2023-03-31$-0.48$-0.40+16.7%$21000.00

Frequently asked questions

Has Altimmune Inc beaten earnings estimates?
Altimmune Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +12.7% over the last 4 quarters.
How does ALT stock react to earnings?
ALT stock has moved an average of +0.4% in the trading day following earnings over its last 2 reports, with positive reactions in 50% of those quarters.
What is Altimmune Inc's revenue growth rate?
Altimmune Inc reported year-over-year revenue growth of +420.0% in its most recent quarter, with EPS growing +18.2% year-over-year.